Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.31 USD
+0.03 (2.34%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.30 -0.01 (-0.76%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.31 USD
+0.03 (2.34%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.30 -0.01 (-0.76%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Zacks News
Are You Looking for a Top Momentum Pick? Why Clearside Biomedical, Inc. (CLSD) is a Great Choice
by Zacks Equity Research
Does Clearside Biomedical, Inc. (CLSD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Clearside Biomedical (CLSD) Enters Oversold Territory
by Zacks Equity Research
Clearside Biomedical (CLSD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0.00% and -75.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (CLSD) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Clearside Biomedical Inc (CLSD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clearside Biomedical Inc (CLSD) delivered earnings and revenue surprises of 22.22% and 2.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -75.00% and -67.06%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Clearside Biomedical Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Clearside Biomedical.
Biotech Leading in Q4: Best ETFs & Stocks
by Sweta Killa
We highlight five biotech ETFs and stocks that are leading the market in Q4.
Is the Options Market Predicting a Spike in Clearside Biomedical (CLSD) Stock?
by Zacks Equity Research
Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -6.25% and 182.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 59.46% and -10.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Options Traders Expect Huge Moves in Clearside Biomedical (CLSD) Stock
by Zacks Equity Research
Clearside Biomedical (CLSD) needs investors to pay close attention to the stock based on moves in the options market lately.
Surging Earnings Estimates Signal Good News for Clearside (CLSD)
by Zacks Equity Research
Clearside (CLSD) is seeing positive earnings estimate revisions suggesting that it could be a solid choice for investors.
Clearside BioMedical (CLSD) is Oversold: Can It Recover?
by Zacks Equity Research
Clearside BioMedical, Inc. (CLSD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock